The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

E. C. Cheon; W. Small; M. J. Strouch; S. B. Krantz; A. Rademaker; M. F. Mulcahy; A. B. Benson; D. J. Bentrem; M. S. Talamonti

doi:10.1002/jso.21598

The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

E. C. Cheon, W. Small, M. J. Strouch, S. B. Krantz, A. Rademaker, M. F. Mulcahy, A. B. Benson, D. J. Bentrem, M. S. Talamonti

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.

Original language	English (US)
Pages (from-to)	539-542
Number of pages	4
Journal	Journal of surgical oncology
Volume	102
Issue number	5
DOIs	https://doi.org/10.1002/jso.21598
State	Published - Oct 1 2010

Keywords

Avastin
Bevacizumab
Chemoradiation
Postoperative complication

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jso.21598

Cite this

@article{ff41e869482f4a1899066d665a19f838,

title = "The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection",

abstract = "Bevacizumab (Avastin{\texttrademark}; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.",

keywords = "Avastin, Bevacizumab, Chemoradiation, Postoperative complication",

author = "Cheon, {E. C.} and W. Small and Strouch, {M. J.} and Krantz, {S. B.} and A. Rademaker and Mulcahy, {M. F.} and Benson, {A. B.} and Bentrem, {D. J.} and Talamonti, {M. S.}",

year = "2010",

month = oct,

day = "1",

doi = "10.1002/jso.21598",

language = "English (US)",

volume = "102",

pages = "539--542",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

AU - Cheon, E. C.

AU - Small, W.

AU - Strouch, M. J.

AU - Krantz, S. B.

AU - Rademaker, A.

AU - Mulcahy, M. F.

AU - Benson, A. B.

AU - Bentrem, D. J.

AU - Talamonti, M. S.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.

AB - Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.

KW - Avastin

KW - Bevacizumab

KW - Chemoradiation

KW - Postoperative complication

UR - http://www.scopus.com/inward/record.url?scp=77957372010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957372010&partnerID=8YFLogxK

U2 - 10.1002/jso.21598

DO - 10.1002/jso.21598

M3 - Review article

C2 - 20812264

AN - SCOPUS:77957372010

SN - 0022-4790

VL - 102

SP - 539

EP - 542

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 5

ER -

The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this